Scroll to top

Scroll to top

News Releases

Home
Investors
News Releases

News Releases

Month Year

Month Year

Investor Alerts

October 1, 2025

Immunic to Participate in Scientific and Investor Conferences in October
September 25, 2025

Immunic Presented Key Vidofludimus Calcium Data at the 41st Congress of ECTRIMS, Highlighting Its Potential in Multiple Sclerosis
September 9, 2025

Immunic Receives Notice of Allowance for United States Patent Protecting Vidofludimus Calcium's Dose Strengths in Progressive Multiple Sclerosis
September 4, 2025

Immunic to Participate in Investor and Scientific Conferences in September
August 7, 2025

Immunic, Inc. Reports Second Quarter 2025 Financial Results and Provides Corporate Update
June 24, 2025

Immunic Reports New, Positive Long-Term Open-Label Extension Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis
June 5, 2025

Immunic Announces Completion of Enrollment for Both Phase 3 ENSURE Trials in Relapsing MS and Presents Additional Data Underlining Positive Outcome of Phase 2 CALLIPER Trial in Progressive MS
June 3, 2025

Immunic, Inc. Announces Closing of Oversubscribed $65 Million Underwritten Public Offering
June 2, 2025

Immunic to Participate in Investor, Scientific and Industry Conferences in June
May 29, 2025

Immunic, Inc. Announces Pricing of Oversubscribed $65 Million Underwritten Public Offering

Show per page